These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 22529099)

  • 1. Novel aspects of mevalonate pathway inhibitors as antitumor agents.
    Thurnher M; Nussbaumer O; Gruenbacher G
    Clin Cancer Res; 2012 Jul; 18(13):3524-31. PubMed ID: 22529099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological inhibitors of the mevalonate pathway activate pro-IL-1 processing and IL-1 release by human monocytes.
    Massonnet B; Normand S; Moschitz R; Delwail A; Favot L; Garcia M; Bourmeyster N; Cuisset L; Grateau G; Morel F; Silvain C; Lecron JC
    Eur Cytokine Netw; 2009 Sep; 20(3):112-20. PubMed ID: 19825520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mevalonate pathway: a review of clinical and therapeutical implications.
    Buhaescu I; Izzedine H
    Clin Biochem; 2007 Jun; 40(9-10):575-84. PubMed ID: 17467679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mevalonate Pathway and Human Cancers.
    Bathaie SZ; Ashrafi M; Azizian M; Tamanoi F
    Curr Mol Pharmacol; 2017; 10(2):77-85. PubMed ID: 26758953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cholesterol and beyond - The role of the mevalonate pathway in cancer biology.
    Göbel A; Rauner M; Hofbauer LC; Rachner TD
    Biochim Biophys Acta Rev Cancer; 2020 Apr; 1873(2):188351. PubMed ID: 32007596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interconnection of Estrogen/Testosterone Metabolism and Mevalonate Pathway in Breast and Prostate Cancers.
    Mokarram P; Alizadeh J; Razban V; Barazeh M; Solomon C; Kavousipour S
    Curr Mol Pharmacol; 2017; 10(2):86-114. PubMed ID: 26758947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway.
    Shipman CM; Croucher PI; Russell RG; Helfrich MH; Rogers MJ
    Cancer Res; 1998 Dec; 58(23):5294-7. PubMed ID: 9850051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel prospects of statins as therapeutic agents in cancer.
    Pisanti S; Picardi P; Ciaglia E; D'Alessandro A; Bifulco M
    Pharmacol Res; 2014 Oct; 88():84-98. PubMed ID: 25009097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of the mevalonate pathway affects epigenetic regulation in cancer cells.
    Karlic H; Thaler R; Gerner C; Grunt T; Proestling K; Haider F; Varga F
    Cancer Genet; 2015 May; 208(5):241-52. PubMed ID: 25978957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulatory properties of statins and rho gtpases prenylation inhibitiors to stimulate melanoma immunogenicity and promote anti-melanoma immune response.
    Sarrabayrouse G; Pich C; Teiti I; Tilkin-Mariame AF
    Int J Cancer; 2017 Feb; 140(4):747-755. PubMed ID: 27616679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lycopene induces cell growth inhibition by altering mevalonate pathway and Ras signaling in cancer cell lines.
    Palozza P; Colangelo M; Simone R; Catalano A; Boninsegna A; Lanza P; Monego G; Ranelletti FO
    Carcinogenesis; 2010 Oct; 31(10):1813-21. PubMed ID: 20699249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Statins and protein prenylation in cancer cell biology and therapy.
    Garcia-Ruiz C; Morales A; Fernandez-Checa JC
    Anticancer Agents Med Chem; 2012 May; 12(4):303-15. PubMed ID: 22413970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Translating the effects of statins: from redox regulation to suppression of vascular wall inflammation.
    Antonopoulos AS; Margaritis M; Shirodaria C; Antoniades C
    Thromb Haemost; 2012 Nov; 108(5):840-8. PubMed ID: 22872079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multilevel modulation of the mevalonate and protein-prenylation circuitries as a novel strategy for anticancer therapy.
    Konstantinopoulos PA; Papavassiliou AG
    Trends Pharmacol Sci; 2007 Jan; 28(1):6-13. PubMed ID: 17150261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the Mevalonate Pathway in Cancer.
    Juarez D; Fruman DA
    Trends Cancer; 2021 Jun; 7(6):525-540. PubMed ID: 33358111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer.
    Graaf MR; Richel DJ; van Noorden CJ; Guchelaar HJ
    Cancer Treat Rev; 2004 Nov; 30(7):609-41. PubMed ID: 15531395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined inhibition of the mevalonate pathway with statins and zoledronic acid potentiates their anti-tumor effects in human breast cancer cells.
    Göbel A; Thiele S; Browne AJ; Rauner M; Zinna VM; Hofbauer LC; Rachner TD
    Cancer Lett; 2016 May; 375(1):162-171. PubMed ID: 26968247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevalonate pathway, impairing Ras membrane localization in prostate cancer cells.
    Oades GM; Senaratne SG; Clarke IA; Kirby RS; Colston KW
    J Urol; 2003 Jul; 170(1):246-52. PubMed ID: 12796698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-cancer therapy: targeting the mevalonate pathway.
    Swanson KM; Hohl RJ
    Curr Cancer Drug Targets; 2006 Feb; 6(1):15-37. PubMed ID: 16475974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the mevalonate pathway for improved anticancer therapy.
    Fritz G
    Curr Cancer Drug Targets; 2009 Aug; 9(5):626-38. PubMed ID: 19508172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.